Raben, D. Curriculum Vitae 1 | P a g e Raben CV 6... · Raben, D. Curriculum Vitae 1 | P a g e David Raben, MD June 1, 2017 Professor And Associate Scientist

Raben, D. Curriculum Vitae 1 | P a g e

David Raben, MD June 1, 2017

Professor And Associate Scientist

Marsico Family Endowed Chair in Head and Neck Cancer Research

Department of Radiation Oncology

University of Colorado Denver

1665 Aurora Court, Suite 1032 MSF706 Aurora, CO 80045

P: 720-848-0116 / F: 720-848-0238

[email protected]

Date of Birth: June 6, 1963 Place of Birth: New York, New York

Citizen of: United States

Postgraduate Education

1995 Diplomat – American Board of Radiology Certification Examination (Radiation Oncology)

2006 Diplomat - American Board of Radiology Re--Certification Examination (Radiation Oncology) 2016 Diplomat - American Board of Radiology Re--Certification Examination (Radiation Oncology)

Postgraduate Education

1993 – 1994 Chief Resident, Radiation Oncology. The Johns Hopkins Hospital – Baltimore, MD

1991 – 1993 Resident, Radiation Oncology. The Johns Hopkins Hospital – Baltimore, MD 1990 – 1991 Transitional Year. University of Hawaii Medical School – Honolulu, HI

Undergraduate/Graduate Education 1985 – 1990 The Bowman Gray School of Medicine – Wake Forest University, Winston Salem, NC (M.D.)

1981 – 1985 Duke University – Durham, NC (B.A.)

Current Academic Appointments

2007 Professor, Department of Radiation Oncology. University of Colorado Denver 2001 – 2007 Associate Professor, Department of Radiation Oncology. University of Colorado Denver

1998 – 2001 Assistant Professor, Department of Radiation Oncology. University of Colorado Denver

Previous Academic Appointments

1994 -1998 Assistant Professor and Associate Scientist, University of Alabama Comprehensive Cancer

Center

Current Hospital and Professional Appointments

1998 Staff Privileges. University of Colorado Hospital – Aurora, CO

1998 Staff Privileges. Denver Health Medical Center – Denver, CO

1998 Consulting Privileges. Denver Veterans Administration Medical Center – Denver, CO

Previous Hospital and Professional Appointments

1996 – 1998 Residency Program Director, Department of Radiation Oncology. University of Alabama - Birmingham, AB

1994 – 1998 Consulting Privileges. Veterans Administration Medical Center – Birmingham, AB

Medical Licensure

Colorado, 1998- #37178 (current)

mailto:[email protected]


Alabama, 1994-1998 (expired)

Awards and Honors

2015 Selected for the American Society of Clinical Oncology Ambassador Program for Multidisciplinary

Cancer Management Courses 2014 Selected as one of 30 faculty to participate in Univ. of Colorado CCTSI Leadership in Team Science

Program (LITeS) 2009 Honored by Cancer League of Colorado for contributions in cancer research

2006 Elected University of Colorado School of Medicine Faculty Senate Secretary

2003 Outstanding Teacher Award. University of Colorado Denver

2001 SPORE Career Development Award. Tobacco Related Malignancies Program. University of Colorado

Denver

1999 Invited participant. Gordon Research Conference. Ventura, CA 1997 Travel Grant Award. European Society for Therapeutic Radiology and Oncology

1996 Invited participant. Methods in Clinical Cancer Research Workshop. Vail, CO

1995 Invited participant. Molecular Biology in Clinical Oncology Workshop. Aspen, CO

1990 C. B. Dean Memorial Award for Outstanding Performances in Clinical Oncology. The Bowman Gray

School of Medicine

1988 Summer Research Fellowship. National Institutes of Health 1987 First Place –Student Research Presentations. The Bowman Gray School of Medicine

1987 Alpha Omega Alpha Research Fellowship

1987 Student Research Assistant Award. Professional Oncology Education Program. The Bowman Gray

School of Medicine

Current Major Professional Memberships

2013 Developmental Therapeutics Committee (NRG Oncology) 2012 Lung Cancer and Lung Cancer Working Group Committee (SWOG)

2006 The American Head and Neck Cancer Society (AHNS)

2005 The International Association for the Study of Lung Cancer (IASLC) 2001 American Association of Cancer Research (AACR)

1998 American Society of Clinical Oncology (ASCO)

1998 American College of Radiology (ACR) 1995 American Society of Radiation Oncology (ASTRO)

Current Professional Activities

1. ASCO Ambassador Multidisciplinary Cancer Management Courses

2. ASTRO Abstract Reviewer: Head and Neck Cancer 3. Reviewer for Italian Association for Cancer Research (IACR)

4. Leadership for Innovative Team Science (LITeS) Program through CCTSI

5. NCI Head and Neck Cancer Steering Committee, Immunotherapy Task Force

6. ASCO/IAEA Cancer Division of Programme of Action for Cancer Therapy

7. Lung, Head and Neck T32 Training Grant Committee 8. Past Chair, Planning Committee, ASTRO/ASCO Head and Neck Cancer Symposium, AZ

9. Developmental Therapeutics Committee Co-Chair (RTOG/NRG)

10. University of Colorado School of Medicine Admissions Executive Committee 11. IASLC Program Comm. For 2015 International Lung Cancer Symposium, Denver CO

12. University of Colorado Cancer Committee

13. Southwest Oncology Group Radiation Oncology Committee 14. NCCN Guidelines for Prostate Cancer Committee


15. Foundations of Doctoring Program for First Year Medical Students

16. Problem Based Learning Full Teaching Member Past Professional Activities

2013 Chair, ASTRO/ASCO Head and Neck Cancer Symposium,

2012 University of Colorado Denver Clinical Strategic Task Force Committee 2012 Chair-Elect, ASTRO/ASCO Head and Neck Cancer Symposium

2009 Program Committee: 2nd ASTRO/ASCO Head and Neck Cancer Symposium, Scottsdale AZ

2009 GU Radiation Oncology Sub-Committee Chair, SWOG 2009 University of Colorado School of Medicine PBL “Molecules to Medicine” Lectures

2008 Program Chair: ASTRO Presidential Symposium on Targeted Therapies in Cancer, Boston MA

2007 Head and Neck Cancer Steering committee, Radiation Therapy Oncology Group

2007 Program Director Co-Chair, ASTRO/ASCO Head & Neck Cancer Symposium, Palm Springs CA

2006 Moderator – ASTRO Presidential Symposium on HNC, Session IV 2005 Director- Radiological Sciences Core for UCCC

2005 UCH Hospital Credentialing Committee

2005 Education Committee, American Society of Therapeutic Radiology and Oncology

2005 Lung Cancer Program Planning Committee, American Society of Clinical Oncology

2005 Co-Moderator, Head and Neck Poster Discussion Session, 47th Meeting of the American

Society of Therapeutic Radiology and Oncology, Denver, CO 2004 American Society of Clinical Oncology Publications Committee

2004 American Society of Therapeutic Radiology and Oncology Steering Committee on Promoting

Research

2002 American Society of Therapeutic Radiology and Oncology Translational Research Committee

2002 The Scientific Advisory Board of the Cancer League of Colorado (CLC)

2002 American Society of Clinical Oncology – Program Committee Member – Department of Education, Science & Publications

2002 UCCC Hormone Related Malignancies Search Committee 2002 UCHSC -- Cancer Investigations Core Search Committee

2002 UCCC K-12 Mentor for Dr. Elaine Weng – Radiation Oncology

2001 UCHSC Medical School Admissions Committee 2001 University of Colorado Comprehensive Cancer Center, Gastrointestinal Tumor Working

Group

2000 ASTRO Refresher Course Committee 2000 ASTRO Young Leadership Committee 2000 UCHSC Medical School Advisory Committee

1999 American College of Radiology Committee Standards For Radiation Oncology, Anal/Rectal

Cancer Panel 1998 Medical Student Mentorship Program, University of Colorado Health Science Center (UCHSC)

1998 Gastrointestinal Steering Committee, Radiation Therapy Oncology Group (RTOG)

1998 Co-Section Head, Head/Neck Tumor Working Group, University of Colorado Health Sciences Center

1997 - 1998 Medical Student Mentorship Program, University of Alabama at Birmingham

1996 - 1997 National Comprehensive Cancer Network Expert Panel on Unknown Primary Cancer, University of Alabama at Birmingham Cancer Center Representative

1996 - 1998 Section Head – Gastrointestinal Working Group, University of Alabama at Birmingham,

Comprehensive Cancer Center


Ad Hoc Reviewer

2015 ASCO Educational Book

2014 ASCO Educational Book

2013 Cancer Research

2011 Clinical Genitourinary Cancer 2011 Radiation Oncology

2005 Molecular Cancer Therapeutics

2005 Head and Neck

2004 British Journal of Cancer

2003 International Journal of Radiation Oncology Biology Physics

2002 Clinical Cancer Research 1997 Journal Clinical Oncology

Editorial Boards

2005 – 2006 International Journal of Cancer

2011 - 2014 Head and Neck 2014 - Clinical Genitourinary Cancer

Invited Local/National/International Presentations and Visiting Professorships

2017 CCTSI LiTES Program invited speaker, “Meetings, Death and Taxes”, April 2017 International Congress on Innovative Approaches in Head and Neck Cancer; Discussant Oral

Abstracts, Barcelona, Spain, March

2017 “Radiation Therapy and Immunotherapy Combinations: Becoming the Fire starter Rather than the Fire.” Radiotherapy Innovations in Advanced Radiotherapy Research: MCRC Showcase. Manchester,

United Kingdom. March

2017 ASCO Multidisciplinary Cancer Management Course: Colorectal and Anal Cancer, Marrakech, Morocco, February

2016 “Radiation and Immunotherapy Challenges in HNC: Are we the Fire or the Firestarter?” 2nd New

Horizons in Immunotherapy for Head and Neck Cancer. La Jolla, California. December 2016 “The Field of Radiation Oncology: Like a Rolling Stone-but with a Direction Home!” Department of

Medicine Grand Rounds, University of Colorado-Denver. December

2016 “Radiation and Immunotherapy: Are we the Fire or the Firestarter?”, Tumor Microenvironment and Immune Checkpoints Annual Retreat. Cancer Cell Biology Program,

University of Colorado-Denver. October 2016 “The role of immunotherapy in the treatment of head and neck cancer: Emerging targets and new

agents”, Hellenic Society of Head and Neck Cancer 1st Congress on Head & Neck Cancer. Athens,

Greece. October

2016 “Optimizing Clinical Trials in Radiation Oncology through Public-Private Collaborations”, ASTRO 58th

Annual Meeting. Boston, MA. September

2016 “Development radiotherapy and immune oncology trials: the experience of an academic radonc inside big pharmas”, ESTRO International Conference on Immunotherapy-Radiotherapy

Combinations. Villejuif, France. September-October

2016 “Radiation and Immunotherapy – Trial Design Considerations”, FDA. Silver Spring, MD. September 2016 “Prospective Trials in Head and Neck Cancer”, AHNS 9th International Conference. Seattle, WA. July

2016 “Adjuvant postoperative Therapy-Indications for Treatment after Oral Cancer Surgery”, AHNS 9th

International Conference. Seattle, WA. July


2016 “Current Management of Oral Cavity Cancer – Indications for Adjuvant Treatment”, AHNS 9th

International Conference. Seattle, WA. July 2016 "Phase I Trial Results of Olaparib, Cetuximab and Radiation for Patients with Heavy Smoker Locally

advanced head and neck cancer", ESTRO 35 Congress. Turin, Italy. April

2016 “What’s the road to success in improving HNC outcomes” Visiting Professor Lecture. Memorial Sloan-Kettering Cancer Center. New York, NY. April

2015 “Getting Out Of The Box: Managing Head and Neck cancer for the Next 5 Years” Princess Margaret

Hospital Grand Rounds, December 2015 “Inhibiting DNA Repair and Immune Suppression in Head and Neck Cancer”, University of Miami

Cancer Grand Rounds. Toronto, CA. November

2015 “Decision-Making in Early Stage Prostate Cancer”, Rocky Mountain Cancer Conference, University of

Colorado, November

2015 “Management of Head and Neck Cancer”, ASCO MCMC Program, Zimbabwe, September 2015 “Role of Radiotherapy in Rectal Cancer”, ASCO MCMC Program, Zimbabwe, September

2015 “Why, when and how should oncologists work together as a multidisciplinary team?” ASCO MCMC

Program, Zimbabwe, September

2014 “Best of the Multidisciplinary Head and Neck Symposium” 2014 ASCO Annual Meeting.

Chicago, IL. May

2014 “Molecular, Immunologic and Radiation Strategies For High Risk Prostate Cancer: What’s On The Horizon?” 15th Annual Sun Sand and Seeds Conference. Boca Raton, FL. March

2014 “The Modular Road to Defining and Targeting High-Risk Head and Neck Patients” 2014

Multidisciplinary Head and Neck Cancer Symposium. Scottsdale, AZ. February

2014 “Oropharynx Cancer and Try Our RoboticS (TORS)” ACRO Annual Meeting. Orlando, FL. February

2013 “Head and Neck Cancer and our Future” Moffitt Cancer Center Grand Rounds. Tampa, FL. December

2013 “Opportunities for Radiation and DNA Repair Inhibition – Stopping the Mario Brothers” UNC Visiting Professor. Chapel Hill, NC. October

2013 “DNA Repair Inhibition and HNC… and other stuff” Visiting Professor Resident Lecture. MD Anderson

Cancer Center. Houston, TX. September 2013 “Management of P16 (-) Head and Neck Cancer” Visiting Professor Lecture. Memorial Sloan-Kettering

Cancer Center. New York, NY. May 2013 “Managing P16(-) head and neck cancer: new avenues for success – without the added morbidity”. UC

Davis Visiting Professor Lecture. Sacramento, CA. April

2013 “Randomized trials on EGFr targeting and biological modifiers” 4th ICHNO Conference. Barcelona, Spain. February

2013 “SBRT treatment of oligimetastate SCLC after chemotherapy” IASLC Lung Cancer Congress.

Santa Monica, CA. February 2013 “Developmental Therapeutics” RTOG Spring Meeting. San Diego, CA. January

2012 “A Multidisciplinary approach to personalizing the treatment of head and neck cancers.” IMER Live

Presentation. Baptist Hospital. Pensacola, FL. June 2012 “Biologics and Radiation for HNC in 2012 – What’s next on the horizon?” MCD. Boulder, CO. January

2012 “Stereotactic Body Radio-ablation in Head and Neck Cancer”. ASTRO Head and Neck Cancer

Symposium. Scottsdale, AZ. January 2012 “New Insight in DNA repair targeting and radiotherapy in head and neck cancer.” International

Conference on Translational Research in Radiation Oncology. Geneva, Switzerland. February

2012 “A Multidisciplinary approach to personalizing the treatment of head and neck cancers.” IMER Live Presentation. Walter Reed National Army Base. Bethesda, MD. April

2012 “If I was in Dallas and could treat head and neck cancer anyway I want in 2012…here is what I would

do.” University Texas Southwestern Visiting Professorship. Dallas, TX. April

2011 22nd LH Gray International Conference: Realizing the potential of drug/radiation interactions in

cancer treatment. “Biological aspects of radiotherapy targets.” Manchester, UK. February 2011 ASCO GU Symposium. “Best of Journals: Prostate Cancer.” Orlando, FL. February


2011 International Symposium “Advances and Perspectives in Thoracic and Upper Aerodigestive

Malignancies.” Athens, Greece. March 2011 ASCO Annual Meeting. “Integration of Targeted Therapy with Radiation”. Chicago, IL. June

2011 “Conventional and Biologic Management of HNC in 2012: What’s a Buckeye to do?” Ohio St.

Grand Rounds. Columbus, Ohio. November 2010 “Management of Oropharynx Cancer – Case Presentations, 2nd ASTRO/ASCO Head and Neck cancer

Symposium. Scottsdale, AZ. February

2010 “What Biologics and New Paradigms Should We Look at with Radiation Therapy to Improve Outcomes?” SWOG Translational Radiation Oncology Symposium. April.

2010 “Updates on the Management of Head and Neck Cancer in 2010” UCSF Grand Rounds, Radiation

Oncology. San Francisco, CA. April.

2010 “Radiation Combined Strategies in the Clinic” AstraZeneca MedImmune 2010 Cross Alliance Scientific

Symposia. Alderley Park. Macclesfield, UK. June 2010 Annual Community Oncology Research Forum. Dallas, TX. August

2010 “New Insight in Molecular Targeting and Radiotherapy” ESTRO 29. Barcelona, Spain. September.

2010 “Targeted Therapies and Radiation in Head and Neck Cancer: Picking the Next Winner” Mount Sinai

Comprehensive Cancer Center Grand Rounds. Miami Beach, FL. October

2009 9th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. The Fairmont Miramar

Hotel. Santa Monica, CA. February 18-21 2009 “Are We Radiation Therapists or Oncologists with Radiation Expertise? Visiting Professor Lecture.

Stanford Cancer Center, Radiation Oncology Rounds. Palo Alto, CA

2009 13th Annual World Congress of Lung Cancer Meeting. San Francisco, CA. July 31 - August 4

2009 Thyroid and Neoplasm’s Symposium. Denver, CO. September 11

2009 “Management of Head/Neck Cancer.” VA MC Grand Rounds. Denver CO. December 15

2008 “Targeted Therapies in HNC: EGFR inhibition worked, what’s the next step?” Cancer Center Grand Rounds. University of Geneva. Geneva, Switzerland.

2008 “Targeted Therapies in HNC: EGFR inhibition worked, what’s the next step?” CIOCC Oncologia

Medica. Madrid, Spain 2008 “No Level I Evidence for Use of Induction Chemotherapy in HNC” 44th Annual American Society of

Clinical Oncology meeting. Chicago, IL. 2008 “Targeted Therapies and Radiation: What lies beyond EGFR inhibition?” 7th International Head and

Neck Conference. San Francisco, CA.

2008 “Updates on the UCCC Lung SPORE Program” Semi-annual RTOG meeting. Philadelphia, PA. 2008 “Anti-Angiogenics and Radiation in Lung Cancer” 5th Annual Symposium Combined Modality

Therapy. University Texas Southwestern. Dallas, TX.

2008 “Treatment Options For Head and Neck Cancer: Where are we and where are we going?” Visiting Professor Lecture. KU Cancer Center Grand Rounds. Kansas City, KS.

2007 “The Role of Targeted Agents and Radiation in Thyroid Cancer” Endocrinology Grand Rounds.

UCHSC. January 2007 “The Evolving Role of Targeted Therapy and Radiation In Cancer Management” DUKE University

Grand Rounds. Durham, NC. February

2007 ‘The Evolving Role of Targeted Therapy and Radiation in Cancer Management” OHSC Grand Rounds. Portland, OR. February

2007 “The Evolving Role of Targeted Therapy and Radiation in Cancer Management” South West

Oncology/Hematology Clinic. San Antonio, TX. March 2007 “Targeted Therapies in HNC: Where are we headed next?” Christies Hospital. Manchester, UK.

2007 “Targeted Therapies in HNC: EGFR inhibition worked – what’s next?” Institute Gustave Roussy,

Radiation Oncology. Paris, France.

2006 “Update on the toxicity and response of a Phase I study of Iressa and radiation or chemoradiation in

patients with locally advanced squamous cell carcinoma of the head and neck” ICTR meeting. Luganno, Switzerland. March (CME)


2006 “Beyond EGFR Inhibition - what else is out there on the horizon for radiation oncology?” – University

of Texas Southwestern Advances in Lung and HNC Symposium. March (CME) 2006 “Updates on the Management of Esophageal Cancer with Radiation in 2006” Vanderbilt University

Department of Radiation Oncology residents didactic. Nashville, TN. July

2006 “Using Biologics to Enhance Radiation in 2006” Vanderbilt Basic Sciences Grand Rounds. Nashville, TN. July (CME)

2006 “Clinical Issues with EGFR Inhibition and Radiation”: 2006 Translational Research in Radiation

Oncology, Physics and Biology Symposium. Boston, MA. September (CME) 2006 “Small Molecule Tyrosine Kinase Inhibitors and Radiation - EGFR and Beyond” 2nd Annual

Integration of Novel Biologic Therapies and Radiation, ASTRO. Philadelphia, PA. November. (CME)

2006 “Erbitux and Radiation in HNC” 2nd Rencontres Nationales Merck Oncologie. Cannes, France.

December

2006 “Novel Biologics and Radiation in NSCLC in 2006” 6th Annual Targeted Therapies in NSCLC. Santa Monica, CA. January (CME)

2005 “Anti-Angiogenesis Inhibitors and Radiation in the Treatment of NSCLC- Where are we in 2005?” 5th

Annual Targeted Therapies in NSCLC. Steamboat Springs, CO. February 12th. (CME)

2005 “Targeted Agents to Enhance Radiation in HNC and NSCLC - Pre-clinical Studies.” Wake Forest

University Cancer Center. April 13 (CME)

2005 “Overview of Targeted Agents to Enhance Radiation Therapy.” Johns Hopkins Hospital Bi-annual Meeting. June 4

2005 “New Targeted Agents to Enhance Radiation Effects: Where Are We in 2005?” University of

Maryland Visiting Professor Lecture. November (CME)

2005 “New Targeted Agents to Enhance Radiation Effects in HNC: Where Are We in 2005?”

2004 Delaware Society of Clinical Oncology (DSCO), November (CME)

2004 “ZD6474 and Radiation – Pre-Clinical Studies.” Targeted Therapies in Radiation Meeting. Lake Tahoe. July 16-18

2004 CTEP Early Drug Development Fall Meeting – 1). “Review of EGFR Inhibitors and Radiation”; 2). “A

Phase I Study of ZD1839 in Combination with Radiation and Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” Bethesda, Maryland.

2004 “Anti-tumor efficacy of ZD6474, a VEGFR tyrosine kinase inhibitor with additional activity against EGFR tyrosine kinase, alone and in combination with radiotherapy in human head and neck cancer .”

3rd International Chicago Symposium on Malignancies of the Chest and Head and Neck. Chicago, IL.

2004 “Targeted Therapies To Enhance Radiation Therapy – Where Are We in 2004?” University of Utah Huntsman Cancer Center – ENT Grand Rounds. November 5 (CME)

2004 “Targeted Therapies and Radiation in HNC – where are we in 2004?” Mary Corwin Hospital Grand

Rounds. Pueblo, CO. (CME) 2004 “Combining Targeted Therapies and Radiation in the Treatment of Head and Neck Cancer – Where

are we in 2004?” Mayo Clinic HNC Grand Rounds. November 12

2004 “Review of Targeted Agents and radiation in Head and Neck Cancer – Challenges Ahead.” MD Anderson Cancer Biology Division. December 13

2003 “Targeted Therapies in Lung Cancer.” Marbella, Spain. January 15-18

2003 “Modulating Angiogenesis and EGFR To Enhance Radiation” 3rd Annual Roundtable Leader Symposium On Targeted Therapies In Lung Cancer. Aspen, CO. February 5-9

2003 “Modulating EGFR and Angiogenic Signaling To Enhance Radiation Response.” MD Anderson Cancer

Center. May 14 2003 “The Emerging Role of EGFR and COX-2 Inhibitors in the Treatment of Human Cancers: Walk Before

You Run!” 12th International Conference of Radiation Research. Brisbane, Australia. August

2003 Targeted Therapies Review – Post-ASTRO Review Course. Washington University. St. Louis, MO.

December 5

2002 “EGFR and VEGFR Modulation in NSCLC” Oncologia 2002 Il Futuro Oggi. Napoli Palazzo Reale. September 18-21


2002 “ZD6126, A Tumor Vascular Targeting Agent, Potentiates The Effects Of Radiation And ZD1839 In

NSCLC” ASCO Molecular Targets Meeting. San Diego, CA. November 8-11 2002 “EGFR and VEGFR Modulation To Enhance Radiation” University of Indiana Radiation Oncology

Annual Educational Meeting. Indianapolis, IN November 16

2001 “Therapeutic Strategies for Localized Prostate Cancer II” 11th International Prostate Cancer Update. Vail, CO.

2000 “Management of Head and Neck Cancer in the 21st Century” Memorial Hospital. Colorado Springs,

CO. 1999 “Antagonists Against Growth Factor Receptors to Enhance Radiation Against NSCLC” 6th IASLC Lung

Tumor Biology Workshop. Aspen, CO.

1999 “Antagonists Against Growth Factor Receptors to Enhance Radiation in the Treatment of NSCLS and

Head and Neck Cancer” 1st International Chicago Symposium on Malignancies of the Chest and Head

and Neck. Chicago, IL. 1998 “Pancreatic Cancer: Past, Present, Future” Oncology Grand Rounds, University of Alabama

Comprehensive Cancer Center.

1998 “Radiation Standards and Innovations in Non-Small Cell Lung Cancer” sponsored by the Institute for

Continuing Healthcare Education. Birmingham, AL.

1998 “Genetic Radio-Isotope Targeting Strategies (GRITS) for Brain Tumors” sponsored by the American

Brain Tumor Association. Chicago, IL. 1997 “Integration of Gene Therapy and Radiation Therapy” Oncology Grand Rounds. University of Alabama

at Birmingham Comprehensive Cancer Center. Birmingham, AL.

1996 “Strategies to Augment Cancer Radiotherapy Employing Gene Transfer Methods” Emergent

Technologies for the Treatment of Brain Tumors. Lake Tahoe, CA.

Leader – National/International Conferences

1. Chair, 2014 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/American Head and Neck Cancer Society. Scottsdale, AZ 2014

2. Chair-elect, 2012 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/American Head

and Neck Cancer Society. Phoenix, AZ 3. Radiation Oncology Program Co-Chair, 8th International Conference on Head & Neck Cancer,

Toronto, 2012.

4. Program Committee, 2010 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/ American Head and Neck Cancer Society. Scottsdale, AZ

5. Program Committee Co-Chair, 2007 Multidisciplinary Head and Neck Cancer Symposium.

ASTRO/ASCO/ American Head and Neck Cancer Society. Rancho Mirage, CA. Jan.18-20. 6. Organized Fourth Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck

Cancer with Kian Ang, M.D, Ph.D. Miami, FL. February 8-11, 2006.

7. Organized Third Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck Cancer with Kian Ang, M.D, Ph.D. Cancun, MX. February 16-20, 2005.

8. Organized Second Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck

Cancer with Kian Ang, M.D, Ph.D. Jamaica. February 25-29, 2004 9. Organized First Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck

Cancer with Kian Ang, M.D, Ph.D. Puerto Rico. February 5-9, 2003.

Didactic Lectures and Teaching Records at the University of Colorado Denver 2017 “Radiation and Immunotherapy Challenges in HNC: Are we the Fire or the Firestarter?” – Radiation Oncology Residents 2016 “Basics of Immunotherapy and RT” – Radiation Oncology Residents

2015 “Salivary Gland Cancers” – Radiation Oncology Residents


2014 “LDR Brachytherapy for Prostate Cancer” – Radiation Oncology Residents

2014 “Management of Bladder Cancer 2014” – Radiation Oncology Residents 2013 “Thyroid Cancer” – Radiation Oncology Resident Lecture

2013 “Prostate Cancer” – Radiation Oncology Resident Lecture

2012 “Conventional and Biologic Management of HNC in 2012” University of Colorado cancer Center Symposium Series, February

2012 “Prostate Cancer” – Radiation Oncology resident teaching didactic. August

2011 “Pancreas Cancer – what’s a Radiation Oncologist to do?” Surgery Grand Rounds, UCD. April 2011 “Intermediate Prostate Cancer” – Radiation Oncology Residency Teaching Didactic. August

2010 “Management of Nasopharyngeal Cancer” – Radiation Oncology resident Lecture

2009 “Prostate Cancer” – Radiation Oncology residency teaching didactic. September

2009 “Prostate Cancer” – Medical Oncology Grand Rounds. September

2009 “Head and Neck Cancer in Radiation Oncology” – Dermatology Grand Rounds. October 2009 “ENT Research Day” –Guest Speaker, UCD Campus. June

2009 PBL Tutor Sessions for Medical Students (6 sessions between September – March 2010)

2009 “Thyroid Neoplasm Symposium” UCD Campus – September

2009 “Prostate Cancer for VA Patients” VAMC Resident Lecture – December

2008 “Unknown Primary of Head and Neck Cancer” – Radiation Oncology residency teaching didactic. April

2008 Surgery Grand Rounds UCD. May 2008 “Pancreas Cancer” – Radiation Oncology residency teaching didactic. May

2008 UCD Cancer Center Symposium. May

2007 “Deal or No Deal – Radiation and Targeted Therapy” –ENT UCHSC Grand Rounds. March

2006 “Bladder Cancer management in 2006 – a Radiation Oncology Perspective” – UCHSC Urology

Grand Rounds, July

2006 “New Targeted Agents to Enhance Radiation in 2006” – Pediatric Cancer Grand Rounds, August. 2006 “Advances in HNC – Update in Management in 2006” – Radiation therapy nursing seminar, October

(CME)

2006 “Cancer of Unknown Primary” - Radiation Oncology residency teaching didactic 2006 “Oropharynx Cancer Update” - Radiation Oncology residency teaching didactic

2006 “Management of Esophageal Cancer in 2006” - UCHSC Surgery Grand Rounds. December 2005 “Locally Advanced Prostate Cancer in 2005” – Radiation Oncology resident teaching didactic

2005 “Radiation Therapy for Skin cancer in the 21st Century” – Dermatology Grand Rounds - December

2005 “Radiobiology for Dummies” – Radiation Oncology residency teaching didactic 2003 “From Basics to Novel Therapies in HNC” - Medical Oncology Basic seminar series

2002 “Interfering With Growth Factor and Angiogenic Signaling To Enhance Radiation Therapy: A

Preclinical and Clinical Review” – Medical Oncology Basic Seminar series 2001 “EGFR Modulation for Radiosensitization” – Dermatology Department Grand Rounds, UCHSC,

November.

2000 “Pancreatic Cancer Management” -Medical Oncology Basic Seminar Series, UCHSC 1999 “Radiation Biology”, -Surgery Grand Rounds, UCHSC

1999 Invited Speaker, “Pancreatic Cancer,” - Medical Oncology Basic Research Conference, UCHSC

1999 “Management of NSCLC, A Radiation Oncology Perspective,” - Lung Cancer Working Group, UCHSC 1999 “Cholangiocarcinoma: Controversies in Management and Future Therapies”– GI Grand Rounds,

UCHSC

1998 “The 90’s Management to Head and Neck Cancer,” – UCCC Grand Rounds 1998 “Pancreatic Cancer: Past, Present, Future”, Surgery Grand Rounds, UCHSC

Sabbatical Activities

8/2007-3/2008


6 month sabbatical in Manchester, England. Consultant for Astra Zeneca, organized radiation biology seminar

series for oncology division of AZ, developed radiation clinical trials with emerging product teams with novel therapeutics including DNA repair inhibition, initiated pre-clinical studies; visiting

professor and lecturer, Christie’s Hospital Cancer Center; performed re-clinical research at the

Patterson Institute with Dr. Ian Stratford evaluating Src kinase inhibition with radiation. Lead to initiation of Phase I trial of PARP inhibition with radiation and anti-EGFR therapy for locally

advanced head and neck cancer. Organized with AstraZeneca and Dr. Gail Eckhardt a sponsored Italian Cancer fellowship at the University of

Colorado with following mentees:

• Teresa Troiani, M.D. – 2005-2006

• Maria Pia Morelli, M.D. 2006 -2007

2001-2002 6 month sabbatical in Naples, Italy at the University of Naples that focused on combinations of biologics

(EGFR and angiogenic inhibitors) and radiation in lung, pancreas, brain and HNC at the University of

Naples in collaboration with Fortunato Ciardiello, M.D., Ph.D. and Giampaolo Tortora, M.D., Ph.D.;

resulted in multiple publications in peer reviewed journals and ongoing collaborations between the

University of Naples and UCCC.

Medical Student Research Mentorship:

2014 Whitney Summers: Head and Neck cancer database update and analysis

2014 Samuel Tesfalidet: PARP inhibition in head and neck cancer, summer research fellowship

Co- mentor: XiaoJing Wang, M.D., Ph.D. 2013 Tyler Robin, M.D., Ph.D: Impact of submandibular sparing in HNC

(Resulted in recent publication in Head and Neck)

Grants Funded/Completed

Funded/Pending: 2015 NIH/NCI SBIR Solicitation No. 2014-01

Phase II grant: Development of Radiation Modulators during Radiotherapy

Total Costs: $1,500,000 11/1/15 – 10/31/17

PI: James Crapo, MD, PhD

Co-PI: David Raben, MD

2015 A novel strategy to target hypoxic cells in prostate tumor Colorado Clinical and Translational Science Institute

Direct costs: $30,000

01/01/15 - 06/30/15

PI: Gagan Deep

Co-PI: David Raben, M.D.

2014 Southwest Early Clinical Trials Consortium (SECT)

UM1CA186688

Direct costs: $248, 049 03/14/14 – 02/28/19

Colorado PI: Gail Eckhardt, M.D.

Co-PI: David Raben, M.D.


2014 NIH/NCI NRG (Contact PI: Wolmark)

U01CA180868 NRG Oncology Network Group Operations Center

$39,771,934

3/1/14 – 2/28/19 0.60 “NRG Oncology’s primary mission is to improve the lives of adults with cancer by conducting multi-

institutional clinical and translational research trials in seven cancer disease sites that will

define new standards of care, identify and verify useful biomarkers and biomarker-based clinical decision-making, create better risk stratification models, identify under- and over-

treatment scenarios, and create new knowledge leading to greater opportunities for cancer

survivorship.”

Co-Chair, Developmental Therapeutics: David Raben, M.D., Carol Aghajan, M.D., Samuel Jacobs, M.D.

2014 T32CA174648-01

Training in Translational Research of Lung, Head and Neck Cancer

Direct costs: $412,600

04/01/2013 – 03/31/2018

Clinical Mentor

Completed:

2009 Hif-1alpha in Head and Neck Cancer Radiotherapy

Radiation Therapeutics and Biology Study Section, NIH R01

Total Costs: $250,000/year direct cost

PI: Chuan Li, Ph.D.

Co-PI: David Raben, M.D. (5% effort) 4/1/2009 – 3/31/2014

2007 In Vivo Screen For Radiation Sensitizers

Radiation Therapeutics and Biology Study Section, NIH

1 R21 DE017494-01A1 Total Costs: $381, 817

PI: Tin Tin Su, Ph.D.

Co-PI: David Raben, M.D. (10% effort) Score: 166

2007 Evaluation of Nitric Oxide as a Radiosensitizer in NSCLC

SPORE Competing Renewal Principle Project #5 Career development Award Total Costs: ~$50,000 annual

PI: Chuan Li, Ph.D.

Co-PI: David Raben, M.D. (5% effort) 5/01/08-4/30/2013

2006 Cs-137 Irradiator for New Fitzsimons Campus

Radiation Therapeutics and Biology Study Section, NIH 1 S10 RR022466-01A1

Total Costs: $226,060

PI: David Raben, M.D.

2006 Predicting NSCLC and HNSCC Sensitivity to ZD6474 and ZD1839 by Microarray Analysis AstraZeneca pre-clinical research grant

Total costs: $33,005

PI: Barbara Frederick, Ph.D. (funded) Co-PI: David Raben, M.D. (10% effort)


2006 Predicting NSCLC and HNSCC Sensitivity to AZD0530 by Microarray Analysis AstraZeneca pre-clinical research grant

Total costs: $44, 534

PI: Barbara Frederick, Ph.D. (funded) Co-PI: David Raben, M.D. (5% effort)

2005 Microarray Analysis to Predict ZD6474 and ZD1839 Response to Radiation RTOG seed grant

Total costs: $15,000

PI: Barbara Frederick, Ph.D. (funded)

Co-PI: David Raben, M.D. (5% effort)

2005 In Vivo Screen For Radiosensitizers in Head and Neck Cancer

NIH Exploratory/Developmental Research Grant Award (R21)

Total costs: $381, 817

PI: Tin Tin Su. Ph.D.

Co-PI: David Raben, M.D. – 5% effort (resubmitted)

2005 Predicting Tumor Progression and Drug Sensitvity by CpG Methylation and MALDI-TOF (R21/R33)


7/1/2006 – 6/30/09

PI: Barbara Frederick, Ph.D.

Co-PI: David Raben, M.D. – 5% effort (under revision)

2005 A Rapid Screen For Novel Cancer Therapeutics That Synergize With Radiation On Lung Cancer

Xenografts

UCHSC SPORE (Lung) Pilot Grant Total Costs: $35,000

PI: Tin Tin Su, Ph.D. Co-PI: David Raben, M.D. – 5% effort (funded)

2003 Department of Health and Human Services Public Health Services – Telephone Counseling for Head and Neck Cancer – Reducing Barriers To Symptom Management and Palliative Care (R21)


7/1/05 – 6/30/07 PI: Kristen Kilbourn

Co-Investigator: David Raben, M.D. – 5% effort (funded)

Grants Under Development

2016 Dual Targeting of PARP and EGFR in HNSCC

1R01CA181311-01 Total costs: $250,000/year direct costs

PI: David Raben, M.D.

Co PI: Xiao Jing Wang, Ph.D. Submitted February 1, 2013

(re-submission planned for June, 2015)

Manuscripts Published


1. Kucera LS, Raben D, Iyer N, Ricardo MI. Herpes Simplex Virus Type II Infection of Unstimulated

Human T-lymphocytes. Viral Immunol 2:11-16, 1989.

2. Benveniste RE, Raben D, Hill RW, Knott WB, Drummond JE, Arthur LO, Jahrling PB, Morton WR,

Henderson LE, Heidecker G. Molecular Characterization and Comparison of SIV Isolates from Macaques, Mangabeys and African Green Monkeys. J Med Primatial 18:287-303, 1989.

3. Kucera LS, Leak EV, Raben D, Iyer N, Heise E. Herpes Virus Activation of HIV-2 in Human T- lymphocytes. Aids Research and Human Retrovirus 6(5):641-647, 1990.

4. Raben D, Williams J, Abrams RA. The Clinical use of Multimodality Therapy in the Management of

Cancer. In Vivo 8:635-642, 1994

5. Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Grizzle WE, Liu T, Curiel DT.

Enhancement of Radiolabeled Antibody Binding and Tumor Localization through Adenoviral

Transduction of the Human Carcinoembryonic Antigen Gene. Gene Therapy 3:567-580, 1996.

6. Buchsbaum, DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, Liu T, Curiel DT.

Approaches to Enhance Cancer Radiotherapy Employing Gene Transfer Methods. Gene Therapy 3:1042-68, 1996.

7. Vickers SM, Rosenfeld M, Raben D, Sampson L. In Vitro Molecular Chemotherapy for Pancreatic

Cancer. Hep Biliary Assoc. Volume II:1163-1167, 1996.

8. Rosenfeld ME, Vickers SM, Raben D, Wang M, Sampson L, Feng M, Jaffe E, Curiel DT. Pancreatic Carcinoma Cell Killing via Adenoviral Mediated Delivery of the Herpes Simplex Virus Thymidine

Kinase Gene. Annals of Surgery, 225(5):609-618, 1997.

9. Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D, Liu T, Curiel DT, Buchsbaum DJ.

Adenoviral Mediated Delivery of Gastrin Releasing Peptide Receptor Results in Specific Tumor Localization of a Bombesin Analogue In Vivo. Clinical Cancer Research 3:1187-1194, 1997.

10. Miller R, Buchsbaum D, Reynolds P, Douglas J, Gilespie G, Mayo M, Raben D, Curiel D. Differential Susceptibility of Primary and Established Human Glioma Cells to Adenovirus Infection: Targeting Via

the Epidermal Growth Factor Receptor Achieves Fiber Receptor-Independent Gene Transfer. Cancer

Research, 58, 5738-5748. December 15, 1998.

11. Robert F, Raben D, Spencer S. UFT/oral Calcium Folinate plus Radiation in Pancreatic Cancer.

Oncology (Huntingt) Jul; 13(7Suppl 3):127-8, 1999.

12. Tincher SA, Kim RY, Ezekiel MP, Zinsli T, Fiveash J, Raben D, Bueschen JB, Urban DA. Effects of Pelvic

Rotation and Needle Angle on Pubic Arch Interference during Transperineal Prostate Implants. Int. J. Radiation Oncology Biol. Phys., Vol. 47, No. 2, pp-361-363, May 2000.

13. Childs H, Spencer SA, Raben D, Bonner JA, Newsome J, Robert F. A Phase I study of Combined UFT lus Leucovorin and Radiotherapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2000 Jul 1;

47(4):939-44.

14. Childs H, Cole T, Falkenberg E, Smith TJ, Alonso JE, Stannard JP, Spencer SA, Fiveash J, Raben D,

Bonner JA, Westfall AO, Kim RY: A Prospective Evaluation of the Timing of Post-Operative


Radiotherapy for Preventing Heterotopic Ossification Following Traumatic Acetabular Fractures. Int.

J. Radiat Oncol Biol Phys. Jul 15; 47(5):1347-52, 2000

15. Saltz L, Raben D, et al, Rectal Cancer: Presentation with Metastatic and Locally Advanced Disease,

American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000.

16. Madhu J, Merrick S, Coia L, Minsky B, Bader J, Janjan N, Raben D, et al, Anal Cancer, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl),

2000.

17. Tepper J, Bader J, Janjan N, Minsky B, Coia L, Madhu J, Merrick S, Raben D, et al, Locally Unresectable

Rectal Cancer, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000.

18. Rich T, Ota D, Rosenthal S, Minsky B, Bader J, Coia L, Janjan N, Madhu J, Merrick G, Raben D, et al,

Management of Resectable Rectal Cancer, American College of Radiology. American College of

Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000.

19. Gibbs P, Robinson W, Pearlman N, Raben D, Walsh, P, Gonzalez R, Management of Primary

Cutaneous Melanoma of the Head and Neck: The University of Colorado Experience and a Review of

the Literature. Journal of Surgical Oncology; 77:179-185, 2001.

20. Raben D, Helfrich B, Chan D, et al, ZD1839, a Selective Epidermal Growth factor Receptor Tyrosine

Kinase Inhibitor, Alone and in Combination With Radiation and Chemotherapy as a New Therapeutic Strategy in Non-Small Cell Lung Cancer. Seminars in Oncology, Vol. 29, No 1, Suppl 4 (February);

pp37-46, 2002.

21. Raben D, Giampaolo T, Ciardiello F. EGFR-targeted therapies as radiosensitizers: an exciting new

partnership. Signal 3 (3): 20-23, September 2002.

22. Raben D, Bianco C, Helfrich B, Weng E, Tortora G, Ciardiello F, Harari P, Interference with Epidermal

Growth Factor Receptor Signaling: Paradigm For Improving Radiation Response in Cancer Treatment. Expert Review of Anti-Cancer Therapy; 2(4) 461-471, 2002.

23. Bianco C, Tortora G, Bianco R, Caputo R1, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, and Ciardiello F. Enhancement of Antitumor Activity of Ionizing

Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-Tyrosine

Kinase Inhibitor ZD1839 (Iressa). Clinical Cancer Research, 8: 3250-3258, 2002.

24. Di Lorenzo G, Riccardo A, Ciardiello F, Raben D, Bianco C, et al., External beam radiotherapy in bone

metastatic prostate cancer: impact on patients’ pain relief and quality of life. Oncology Reports., 10:399-404, 2003.

25. Raben D, Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. Aug;41 Suppl 1:S15- 22,

2003.

26. Okunieff P, Meyn RE, Teicher BA, Thomas CR Jr, Gaspar LE, Raben D, et al. Report from the Radiation

Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. Am J Clin Oncol. Oct;26(5):522-9, 2003.


27. Raben D, Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol. Apr;14(2):139-52, 2004.

28. Raben D, Helfrich B, Bunn PA Jr. Targeted therapies for non-small-cell lung cancer: biology, rationale,

and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 59(2 Suppl):27-38, 2004.

29. Raben D, Helfrich B. Angiogenesis inhibitors– A rationale strategy for radiosensitization in the

treatment of non-small cell lung cancer? Clinical Lung Cancer Jul;6(1):48-57, 2004

30. Raben D, Chen C, Troiani T and Weng E. Epidermal Growth Factor Receptor Tyrosine Kinase

Inhibitors (EGFR-TKIs) in the Treatment of Head and Neck Cancer – The Next Step. Signal Vol.5 (2)

2004.

31. Raben D, Bianco C, Damiano V, et al. Antitumor Activity of ZD6126, a Novel Vascular-Targeting

Agent, is Enhanced When Combined With ZD1839 (gefitinib, Iressa™) an Epidermal Growth Factor

Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) and Potentiates the Effects of Radiation in a Human

Non-Small cell Lung Cancer (NSCLC) Xenograft Model. Mol Cancer Ther. 2004 Aug;3(8):977-83.

32. Song J, Chen C, Raben D. The Emerging Role of EGFR-Targeted Therapies and Radiation in Cancer of the Head and Neck. Oncology (Huntingt). Dec;18(14):1757-67; discussion 1767, 1771-2, 1777, 2004.

33. Gridelli C, Maione P, Ciardiello F, Rossi A and Raben D. Treatment of locally advanced non small cell

lung cancer in the elderly. Curr Opin Oncol. Mar;17(2):130-134, 2005.

34. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung

cancer. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

35. Ding M, Newman F and Raben D. New radiation therapy techniques for the treatment of head and

neck cancer. Otolaryngol Clin North Am.2005, Apr; 38(2), 371-95 (Review)

36. Damiano V, Melisi D, Bianco C, Raben D, et al., Cooperative Antitumor Effect of Multitargeted Kinase

Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clin Cancer Res. Aug;11(15):5639-5644, 2005.

37. Raben D and Ryan A. Vascular Targeting Agents With And Without Radiation Therapy In Lung Cancer. Clin Lung Cancer. 2005 Nov;7(3):175-9.

38. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I and Raben D. ZD6474, an Example of a Dual EGFR and VEGFR Inhibitor: Its Effects Alone and In Combination with Radiation Therapy – An

Assessment of Pre-Clinical and Clinical Investigations. Int J Radiat Oncol Biol Phys. 2006 Jan

1;64(1):33-7.

39. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, et al. Interim analysis of a prospective

phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45(7):848 -55.

40. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB., Jones CU, Sur R, Raben D, et al.

Cetuximab plus radiotherapy for patients with locally advanced head and neck cancer. N Engl J Med.

2006 Feb 9;354(6):567-78.


41. Ballonoff A, Chen C and Raben D. Current radiation therapy management issues in oral cavity cancer.

Otolaryngol Clin North Am. 2006 Apr;39(2):365-80.

42. Rabinovitch R, Eldridge B, Berkey B, Raben D, Ang KK, Fu K. The impact of baseline nutritional

support on treatment outcome in patients with locally advanced squamous cell cancer of the head and neck treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group

(RTOG) Trial 90-03. Head Neck. 2006 Apr;28(4):287-96.

43. Lewis KD, Dollarhide S, Fitzpatrick JE, Gonzalez R, High WA, McCarter MD, Olsen C, Raben D.

Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass.

Oncology (Williston Park). 2006 Jun; 20(7):763-70.

44. Kavanagh BD, Raben D. Toward a unified target theory in oncology. Future Oncol. 2006 Aug;2(4):435-6.

45. Rothschild B, Shim AH, Irb KB, Hea JA, Garcia M, Sacks PG, Frederick B, Raben D, and Weed SA.

Cortactin Overexpression Regulates Arp2/3 Complex Activity, Motility and Invasion in Carcinomas

with Chromosome 11q13 Amplification. Cancer Res. 2006 Aug 15;66(16):8017-25.

46. Schefter T, Kavanagh B, Raben D, et al. A phase I/II trial of stereotactic body radiation therapy

(SBRT) for lung metastases: Initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol

Phys. 2006 Nov 15;66(4 Suppl):S120-7.

47. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Pasqualetti F, Troiani T, Tacca MD,

Raben D, et al. Synergistic antitumor activity of the multitargeted kinase inhibitor ZD6474 with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006 Dec

1;12(23):7099-107.

48. Helfrich B, Raben D, Chan D, et al. Antitumor activity of the EGFR tyrosine kinase inhibitor gefitinib

(ZD1839, IRESSA™) in NSCLC cell lines and xenografts correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 1;12(23):7117-7125.

49. Harari PM. Cohen RB, Raben D, et al. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S1-3.

50. Willey CD, Murphy BA, Netterville JL, Burkey BB, Shyr Y, Shakhtour B, Kish B, Raben D, Chen C, Song JI, Kane MA, Cmelak AJ. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel

and erythropoietin for high-risk postoperative head and neck cancer patients. Int J Radiat Oncol Biol

Phys. 2007 Apr 1;67(5):1323-31.

51. Frederick B, Hefrich B, Coldren C, Bunn P and Raben D. Epithelial to mesenchymal transition

predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun;6(6):1683-91.

52. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG and Raben D. Phase I trial of gefitinib in combination with radiation or chemoradiation

for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 25:4880-4886,

2007

53. Rusthoven K, Ballonoff A, Raben D and Chen C. Poor Prognosis in Patients with Stage I-II Oral Tongue Squamous Cell Carcinoma. Cancer. 2007 Nov 26;112(2):345-351.


54. Chow L, Chen C and Raben D. EGFR inhibitors and Radiation in HNSCC. Current Cancer Therapy Reviews 2007

55. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine

kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008

Feb;61(2):179-88.

56. M Ding, F Newman, L Gaspar, B Kavanagh, K Stuhr, Raben D, JS Li and C-M Ma. A 4D treatment

planning tool for the evaluation of motion effects on lung cancer treatments. Journal of Physics:

Conference Series 102. (2008).

57. Rusthoven K, Chen C, Raben D, Kavanagh B. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat

Oncol Biol Phys. 2008 May 1;71(1):192-8.

58. Rusthoven K, Flaig T, Raben D and Kavanagh B. High Incidence of Lung Cancer After Non– Muscle-

Invasive Transitional Cell Carcinoma of the Bladder: Implications for Screening Trials. Clinical Lung

Cancer. 2008 Mar; 9(2): 106-11.

59. Rusthoven K, Raben D, Chen C, et al. Effect of Radiation Techniques in Treatment of Oropharynx

Cancer. Laryngoscope. 2008 Apr, 118(4): 635-9.

60. Argiris A, Karamouzis VM, Raben D and Ferris R. Head and Neck Cancer. Lancet (Review) 2008 May

17; 371(9625): 1695-709.

61. Ballonof A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah R, Raben D and Schefter

T. Preoperative capecitabine and accelerated intensity modulated radiotherapy in locally advanced rectal cancer, a Phase II trial. Am Jour of Clin Oncology 2008 June; 31(3); 264-271.

62. Ballonoff A, Raben D, Rusthoven KE, Bassetti M, Kane M, Song JI, Chen C. Outcomes of patients with

n3 neck nodes treated with chemoradiation. Laryngoscope. 2008 Jun;118(6):995-8.

63. E Bradshaw-Pierce, C Steinhauer, Raben D and D Gustafson. Pharmacokinetic-directed dosing of

vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther.

2008 Sep;7(9):3006-17.

64. Rusthoven R, Raben D and Chen C. Improved survival in patients with stage III-IV head and neck

squamous cell carcinoma treated with radiotherapy as the primary local treatment modality. Int J Radiat Oncol Biol Phys. 2008 Oct 1; 72(2); 343-50.

65. Le, Q and Raben D. Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. Semin Radiat Oncol. 2009 Jan;19(1):53-62. Review.

66. Olsen C, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Steigmann S and Raben D. Results of a Phase I Trial of 12 Patients with Locally Advanced Pancreatic Carcinoma

Combining Gefitinib, Paclitaxel and Three-Dimensional Conformal: Report of Toxicity and Evaluation

of Circulating K-ras as a Potential Biomarker of Response to Therapy. Am J Clin Oncol 2009 Apr,

32(2): 115-21.


67. Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor

receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose and sequence-dependent manner. BJU Int. 2009

Jun;103(12):1729-37.

68. Raben A, Rusthoven KE, Sarkar A, Glick A, Benge B, Jacobs D, Raben D. Favorable toxicity and biochemical control using real-time inverse optimization techniques for prostate brachytherapy.

Brachytherapy. 2009 Jul-Sep; 8(3): 297-303.

69. Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A. Freedom from Local and Regional

Failure of Contralateral Neck with Ipsilateral Neck Radiotherapy for Node-Positive Tonsil Cancer:

Results of a Prospective Management Approach. Int J Radiat Oncol Biol Phys. 2009 Aug 1; 74(5);

1365-70.

70. Brechbuhl HM, Min E, Kariya C, Frederick B, Raben D, Day BJ. Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. Free Radic Biol Med. 2009 Sep

15;47(6):722-30.

71. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, hayes DF, Hooks J, Ling C, Meyskens FL Jr,

Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR Jr, Vikram B, Zelefsky MJ, Baker

LH. Report from Radiation Therapy Committee of the Southwest Oncology Group (SWOG): research objectives workshop 2008. Clin Cancer Res. 2009 Sept 15:15(18):5663-70.

72. McCammon R, Kavanagh B, Newell S, Newman F and Raben D. Toxicity assessment of pelvic

Intensity-Modulated Radiotherapy with A hypofractionated simultaneous integrated boost to the

prostate for intermediate- and high-risk localized prostate adenocarcinoma. Int J Radiat Oncol Biol

Phys 2009 Oct 1, 75;2): 413-20.

73. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, Frederick B, Rothschild B,

Raben D, Green TP and Weed S. The Src Inhibitor AZD0530 Suppresses Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Canc Sci Ther. 2009 Nov 1(2): 052-

061

74. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J,

Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between

cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. Erratum in: Lancet Oncol.

2010 Jan;11(1):1

75. Diot Q, Olsen C, Kavanagh B, Raben D, Miften M. Med Phys. Impact of anatomical interventions on the

localization of post-prostatectomy cancer patients. 2010 Feb;37(2):629-37.

76. Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA, Chen C. Survival and Patterns of Relapse in

Patients With Oral Tongue Cancer. J Oral Maxillofac Surg. 2010 Mar; 68(3); 584-9.

77. Chung CH, Raben D. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in

oropharyngeal cancer. J Clin Oncol. 2010 Sep 20;28(27):4103-4.

78. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven K, Swing R and Raben D. A phase I trial of

bortezomib and concurrent external beam radiation in patients with advanced solid malignancies..

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78 (2); 521-6.


79. Rusthoven KE, Feigenberg SJ, Raben D, et al., Initial Results of a Phase I Dose-Escalation Trial of

Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head- and- Neck Cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-5.

80. Diot Q, Olsen C, Kavanagh B, Raben D, Miften M. Dosimetric effect of online image-guided anatomical interventions for postprostatectomy cancer patients.

81. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of

single fraction equivalent dose on local control. Radiat Oncol. 2011 April 8:6(1):34

82. Kavanagh BD and Raben D. Back to the future: a proton pro/con. Oncology (Williston Park) 2011

Jun;25(7):657, 660, 662-3.

83. Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, Wang HM, Prasad S, D'Cruz AK,

Radosevic-Jelic L, Kumar RR, Korzeniowski S, Fijuth J, Machiels JP, Sellers MV, Tchakov I, Raben D.

Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell

carcinoma: A phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol. 2011

Jul;100(1):62-9

84. Edwards A, Gladstone M, Yoon P, Raben D, Frederick B, Su TT. Combinatorial effect of maytansinol

and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul-Aug; 4(4):496-503.

85. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O’Sullivan B, He AZ, Peng Y, Tan AC, Zhou L, Shen J, Han G,

Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D, Bedford JS, Li CY. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011 Jul 3;17(7):860-6

86. Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in

Head and Neck Squamous Cell Carcinoma Cells. Clin Cancer Res. 2011 Aug 1;17(15); 5016-25.

87. Amin NP, Miften M, Kavanagh BD, Raben D, Camidge DR, Thornton D, Rockford N, Gaspar LE. Impact

of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer. J Thorac Oncol. 2011 Sep:6(9); 1553-62.

88. Siddiqui F, Raben D, Lu JJ, Grecula JC, Lo SS, Huang Z, Mayr NA, Teh BS, Yao M. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther. 2011

Sep;11(9):1429-36.

89. Bowles DW, Reddy K, Wine T, Ree A, Raben D, Chen C, Jimeno A. Locoregional recurrence of an HPV-

positive squamous cell carcinoma of the head and neck. Oncology (Williston Park), 2011 Oct;25(11):

1042-8 Review

90. Oberley-Deegan RE, Steffan JJ, Rove KO, Pate KM, Weaver MW, Spasojevic I, Frederick B, Raben D,

Meacham RB, Crapo JD, Koul HK. The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation. PLoS One. 2012;7(9):e44178.

91. Gladstone M, Frederick B, Zhenf D, Edwards A, Yoon P, Stickel S, Delaney T, Chan DC, Raben D, Su TT.

A translation inhibitor identified in a Drosophila enhances the effect of ionizing radiation and taxol in

mammalian models of cancer. Dis Model Mech. 2012 May; 5(3):342-50.


92. Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with

radiation therapy: a case report and review of the literature. Head Neck. 2012 Jul;34(7):1045 -50.

93. Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III

non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10;30(32):3909-12.

94. Amin N, Reddy K, Westerly D, Raben D, DeWitt P, Chen C. Sparing the larynx and esophageal inlet

expedites feeding tube removal in patients with stage III-IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapy. Laryngoscope. 2012 Dec;122(12):2736-42.

95. Kilbourn K, Anderson D, Costenaro A, Lusczakoski K, Borrayo E, Raben D. Feasibility of EASE: A

psychosocial program to improve symptom management in head and neck cancer patients.

Supportive Care in Cancer. 2013 Jan; 21(1); 191-200.

96. Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G. Salivary Gland Cancer. Am Soc Clin

Oncol Educ Book. 2013;2013:257-63.

97. Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, Gutkind JS, Zhao R,

Raben D, ten Dijke P, Refaeli Y, Zhang Q, Wang XJ. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med. 2013 Apr;19(4):421-8.

98. Keysar SB, Astling DP, Anderson RT, WVogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le,

PN, Eagles-Soukup JR, Kabo, SL, Takimotot SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM,

Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Aracroli JJ, Messersmith WA,

Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan A, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics

in defined molecular bins. Mol Oncol. 2013 Aug;7(4):776-90.

99. Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The Prognostic

Significance of Gleason Scores in Metastatic Prostate Cancer. Urol Oncol. 2014 Mar 11; S1078- 1439(14)

100. Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-

based study. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-73.

101. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA,

Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ,

Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May;12(5):686-718.

102. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance

observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate

cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-17

103. Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications

prognostic for survival in men receiving definitive external beam radiation therapy for localized

prostate cancer. Urol Oncol. 2014 Aug 20. pii: S1078-1439(14)00266-X


104. Blumenfeld P, Pfeffer RM, Symon Z, Den RB, Dicker AP, Raben D, Lawrence YR. The lag time in

initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? Br J Cancer. 2014 Aug 12.

105. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC and Le Q-T. p16 protein expression and human papillomavirus

status as prognostic biomarkers of non-oropharyngeal head and neck squamous cell carcinoma. J Clin

Oncol 2014 Sept 29. pii: JCO.2013.54.5228

106. Gregory GN, Eagles J, Keysar SB, Wang G, Glogowska MJ, Altunbas C, Anderson RT, Le PN, Morton JJ,

Frederick B, Raben D, Wang XJ, Jimeno A. Hedgehog signaling drives radioresistance and stroma-

driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014 Dec

1;74(23):7024-36. doi: 10.1158/0008-5472.CAN-14-1346. [Epub ahead of print]

107. Amini A, McDermott JD, Gan G, Bhatia S, Sumner W, Fisher CM, Jimeno A, Bowles DW, Raben D,

Karam SD. Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly

or patients with poor performance. Front Oncol. 2014 Oct 8;4:274. doi: 10.3389/fonc.2014.00274.

eCollection 2014.

108. Papadimitrakopoulou VA1, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT,

Chen CR, Jimeno A, Nedzi L,Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation

therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head

Neck. 2014 Oct 29. doi: 10.1002/hed.23922. [Epub ahead of print]

109. Robin TP, Gan G, Tam M, Westerly D, Riaz N, Karam S, Lee N, Raben D. A Multicenter Review of Contralateral Submandibular Gland Sparing in Locally Advanced Oropharyngeal Cancers: Is it Safe?

Head Neck. 2014 Dec 6. doi: 10.1002/hed.23928 [Epub ahead of print]

110. Reddy K, Strom T, Plimpton R, Kavanagh BD, Petersen J, Wilson S, Maroni P, Raben D. Efficacy of

pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer. J Radiat Oncol (2014) 3:401–407.

111. Dan TD, Raben D, Schneider CJ, Hockstein NJ, Witt RI, Dzeda M, Cormier JF, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node- positive

tonsil cancer: Updated results of a prospective management approach. Oral Oncol. 2015

Jun;51(6):616-21.

112. Amini A, Westerly D, Waxweiler T, Ryan N, Raben D. Dose Painting to Treat Single Lobe Prostate

Cancer Using Targeted External Beam Radiation Therapy Med Dosim. 2015 Autumn;40(3):256-61.

113. Wozniak A, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ,

Gandara D, A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Patients with Inoperable Locally Advanced Stage

III Non-Small Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep;16(5):340-7.

114. Stickel S, Gomes N, Frederick B, Raben D, Su TT. Bouvardin Is A Radiation Modulator With A Novel

Mechanism Of Action Radiat Res. 2015 Oct;184(4):392-403. doi: 10.1667/RR14068.1. Epub 2015

Sep 28.

115. Galloway TJ , Wirth L, Colevas AD, Gilbert J; Bauman JE; Saba NF; Raben D; Mehra R; Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs,


EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell

carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.

116. Yom SS, Diehn M, Raben D. Molecular determinants of radiation response in non-small cell lung

cancer. Semin Radiat Oncol. 2015 Apr;25(2):67-77. doi: 10.1016/j.semradonc.2014.12.007. Epub 2014 Dec 19. Review.

117. Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-Escalated External Beam Radiotherapy (DE-EBRT) Versus Combined

Brachytherapy for Intermediate- and High-Risk Prostate Cancer Using the National Cancer Data

Base.J Urol. 2015 Nov 11. pii: S0022-5347(15)05217-9. doi: 10.1016/j.juro.2015.11.005. [Epub

ahead of print]

118. Kessler ER, Amini A, Wilson SS, Anp-C KB, Raben D, La Rosa FG, Crawford ED. Lymphoepithelioma-

Like Carcinoma of the Urinary Bladder. Oncology (Williston Park). 2015 Jun;29(6):462, C3.

119. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA,

Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF,

Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. Prostate Cancer,

Version 1.2016.J Natl Compr Canc Netw. 2016 Jan;14(1):19-30.

120. Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of

Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial

for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2015 Dec 28. pii:

JCO625970. [Epub ahead of print]

121. Gan GN, Altunbas C, Morton JJ, Eagles J, Backus J, Dzingle W, Raben D, Jimeno A. Radiation dose

uncertainty and correction for a mouse orthotopic and xenograft irradiation model. Int J Radiat Biol. 2015 Dec 21:1-7. [Epub ahead of print]

122. Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk

prostate cancer using the National Cancer Data Base. Urol Oncol. 2015 Dec 11. pii: S1078

1439(15)00556-6. doi: 10.1016/j.urolonc.2015.11.004. [Epub ahead of print]

123. Amini A, Rusthoven CG, Waxweiler TV, Jones BL, Fisher CM, Karam SD, Raben D. Association of

health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad Dermatol. 2015 Dec 6. pii: S0190-9622(15)02267-7. doi: 10.1016/j.jaad.2015.09.054.

[Epub ahead of print]

124. Amini A, Jones BL, Jackson MW, Rusthoven CG, Maroni P, Kavanagh BD, Raben D. Survival outcomes

of combined external beam radiotherapy and brachytherapy vs. Brachytherapy alone for

intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy. 2016 Jan 26. pii: S1538-4721(15)00607-8. doi: 10.1016/j.brachy.2015.11.006. [Epub ahead of print]

125. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W. Development and validation of a staging system for HPV-

http://www.ncbi.nlm.nih.gov/pubmed/26936027


related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 Feb 26. 126. Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016 Mar 11. 127. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. Eur J Cancer. 2016 Mar 29;59:142-151 128. O’Sullivan B, Huang SH, Su J, Garden A, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA,

Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel E-J, Bowles

DW, Raben D, Karam SD, Yu E, Xu W. A Proposal for UICC/AJCC Pre-treatment TNM Staging for HPV- related Oropharyngeal Cancer by the International Collaboration on Oropharyngeal Cancer Network

for Staging (ICON-S): A Comparative Multi-Centre Cohort Study. Lancet Oncol. 17(4):440-51, 2016.

129. Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May;56:1-7. doi: 0.1016/j.oraloncology.2016.02.011. Epub 2016 Mar 12. PMID: 27086480 130. Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote

RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of

Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG

Experience. Int J Radiat Oncol Biol Phys. 2016 Mar 26. pii: S0360-3016(16)00323-0. doi: 10.1016/j.ijrobp.2016.03.011. [Epub ahead of print]

131. Divi V, Harris J, Harari PM, Cooper JS, McHugh J, Bell D, Sturgis EM, Cmelak AJ, Suntharalingam

M, Raben D, Kim H, Spencer SA, Laramore GE, Trotti A, Foote RL, Schultz C, Thorstad WL, Zhang

QE, Le QT, Holsinger FC. Establishing quality indicators for neck dissection: Correlating the number

of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer. 2016 Jul 15. doi: 10.1002/cncr.30204. [Epub ahead of print]

132. Ndarukwa S, Nyakabau A, Chagpar AB, Raben D, Ndlovu N, Kadzatsa W, Eaton VJ, Mafunda P,

Razis E. ASCO Multidisciplinary Cancer Management Course: Connecting lives, cancer care,

education and compassion in Zimbabwe: A pilot for efforts of sustainable benefit? Journal of Global

Oncology 2016.

133. Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, Ghosh D, Bowles DW, Karam

SD. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients

With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base. JAMA

Otolaryngol Head Neck Surg. 2016 Aug 18. doi: 10.1001/jamaoto.2016.2168. [Epub ahead of print]

134. Xiao C, Zhang Q, Nguyen-Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Winquist E, Jones CU, Robinson W, Raben D, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2016 Jul 25. pii: S0360-3016(16)32895-4. doi: 10.1016/j.ijrobp. 2016.07.020 [Epub ahead of print]










135. Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. Cancer. 2016 Oct 11. doi: 10.1002/cncr.30382. [Epub ahead of print] 136. Kim DN, Straka C, Cho LC, Lotan Y, Yan J, Kavanagh B, Raben D, Cooley S, Brindle J, Xie XJ, Pistenmaa D, Timmerman R. Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. Pract Radiat Oncol. 2016 Jun 24. pii: S1879-8500(16)30108-4. doi: 10.1016/j.prro.2016.06.010. [Epub ahead of print] 137. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway

TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-variant as a biomarker of favorable cetuximab response in head and neck cancer: NRG Oncology/RTOG 0522JAMA Oncol. 2016 Dec 22. doi: 10.1001/jamaoncol.2016.5478. [Epub ahead of print]

138. Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS,

Pasquale EB, Wang XJ, Karam SD. Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas. Sci Rep. 2016 Dec 12;6:38792. doi: 10.1038/srep38792

139. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA,

Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Cancer. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 2016 Dec 1. doi: 10.1002/cncr.30449. [Epub ahead of print]

140. Bowles DW, Deutsch E, Raben D. Successes and Failures of Combined Modality Therapies in Head

and Neck Cancer. Semin Radiat Oncol. 2016 Oct;26(4):299-306. doi:10.1016/j.semradonc.2016.05.004. Review.

141. Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK,

Rosenthal DI. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Eur J Cancer. 2016 Sep;64:1-11. doi: 10.1016/j.ejca.2016.05.008.

142. Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ. Patient

characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database. Urol Oncol. 2017 Feb 14. pii: S1078-1439(17)30015-7. doi: 10.1016/j.urolonc.2017.01.013. [Epub ahead of print]

143. Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam

SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. Cancer. 2017 Feb 15;123(4):600-608. doi: 10.1002/cncr.30382

Manuscripts Submitted, Accepted or Under Review

1. Robin TP, Amini A, Lanning RM, Karam S, Raben D. Thyroid gland sparing radiotherapy in the management of head and neck cancer: a single institution prospective approach to assess feasibility, safety, and response. (Under Review: Practical Radiation Oncology)

2. Robin TP, Jones B, Gordon O, Phan A, McDermott J, Goddard J, Raben D, Lanning R, Karam S. A comparative analysis of treatment modalities for sinonasal malignancies: a comprehensive population based approach. (Accepted: Cancer)


3. Cicchini L, Blumhagen R, Westrich J, Meyers M, Warren C, Siska C, Raben D, Kechris K, Pyeon D. High-risk human papillomavirus E7 alters host dna methylome and represses HLA-E expression in human keratinocytes. (Accepted: Scientific Reports)

4. Dheeraj A, Agarwal C, Schlaepfer I, Raben D, Singh R, Agarwal R, Deep G. A novel approach to target hypoxic cancer cells via combining β-oxidation inhibitor etomoxir with radiation. (Submitted: Molecular Cancer)

Textbook Contributions

1. Gaspar, L, Mertens W, Raben D, Evans S. Clinical Aspects and Management of Anal Cancer. Oxford University Press, May 2000.

2. Raben D, Buchsbaum D. Combined External Beam Radiotherapy and Radioimmunotherapy. Targeted Therapy for Cancer. Oxford University Press, London, England, 1999.

3. Raben D. Treatment of Non-Small cell Lung Cancer. Lung Cancer Therapy Annual (3). Martin Dunitz,

2003.

4. Raben D, Kavanagh B and Raben A. American Cancer Society’s A Complete Guide to Prostate Cancer. Chapter 21: What is External Beam Therapy (EBRT). American Cancer Society, pp. 197- 204, 2005.

5. Sartor C, Raben D, O’Neil, B. Chapter 5: Biologics and Interactions with Radiation. Gunderson L,

Tepper J, eds. Clinical Radiation Oncology, 2nd Edition. New York, NY: Churchill Livingstone, 2006.

6. McCammon R, Chen C, Suntha M, and Raben D. Chapter 92. Chemoradiation for Head and Neck

Cancer. 17th Edition of Ballenger's Otorhinolaryngology Head and Neck Surgery. BC Decker

Publisher, 2007.

7. Raben D, Schwer A and Van Houtte P. Targeted Therapies and Radiation in Lung Cancer. Lung

Cancer: Principles and Practice, 4th ed. Williams and Wilkins Publisher. 2009

8. Pugh, TJ, Sartor C, Raben D. Chapter 5: Biologics and Interactions with Radiation. Gunderson L,

Tepper J, eds. Clinical Radiation Oncology, 3rd Edition. New York, NY: Churchill Livingstone, 2010.

9. Raben D, Rusthoven KE: Chapter 5: Combined Modality Therapy in Cancer Management. In:

Anticancer Drug Development: Principles and Practices. Hidalgo M, Eckhardt SG, Garrett-Mayer E, Clendeninn NJ (eds) 2011

10. Carlson J, Licitra L, Locati,L, Raben D, Persson F, Stenman G. Salivary Gland Cancer. Am Soc Clin

Oncol Educ Book. 2013; 2013:257-63.

11. Waxweiler T, Raben D. Chapter 5: Biologics and Interactions with Radiation. Gunderson L, Tepper J, eds. Clinical Radiation Oncology, 4th Edition. New York, NY: Churchill Livingstone, 2014.

Other

1. Patent # 5,902,583, issue date: May 11, 1999: Genetic Induction Of Receptors For Targeted

Radiotherapy; Buchsbaum, Curiel, Khazaeli, Raben, et al., USSN 08/739,826; FY96-000

Abstracts Presented/Published


1. Raben D, Kucera LS, Iyer N, Ricardo, MI. Electron Microscopic Evidence for Co-Infection and

Replication of Herpes Virus and HIV-1 in the same Human T-cell. 5th International AIDS Meeting; Montreal, Canada. June 1989.

2. Raben D, Lee J, Lee DJ: Radiotherapy for Nasopharyngeal Carcinoma: An Analysis of Site of Failure. 35th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology;

New Orleans, Louisiana. November 1993.

3. Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Curiel D. Adenoviral-Mediated

Transduction of Genes Encoding for Surface Receptors to Improve Radioligand Tumor Localization.

10th Annual Scientific Meeting of the Society of Biological Therapy; Williamsburg, Virginia.

November 1-4, 1995.

4. Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Curiel D. Strategies to Augment

Radioimmunotherapy Via Genetic Induction of Receptors for Radioligand Binding. Cancer Gene

Therapy 2:330, 1995.

5. Buchsbaum DJ, Rosenfeld ME, Raben D, Khazaeli MB, Liu T, Curiel DT. Genetic Radioimmunotherapy

of Cancer. 13th International Hammersmith Conference: Advance in the Applications of Monoclonal Antibodies in Clinical Oncology; Chania, Greece May 27-30, 1996.

6. Vickers SM, Rosenfeld M, Raben D, Sampson LK, Phillips JO, Curiel DT. The In Vitro Application of

Molecular Chemotherapy in the Treatment of Pancreatic Cancer. University of Alabama at

Birmingham, Birmingham, Alabama. 2nd World Congress of the International Hepato -Pancreato-

Biliary Association; Bologna, Italy. June 2-6, 1996.

7. Raben D, Buchsbaum DJ, Stackhouse MA, Rosenfeld ME, Mikheeva G, Khazaeli MB, Rogers BE, Curiel

RT. Genetic Induction of Novel Receptors in Tumor Cells Enhances Radiolabeled Peptide Targeting. Cold Spring Harbor Laboratory, Cold Spring Harbor; NY, New York. September 25-29, 1996.

8. Hixon WC, Raben D, Jaffe KA, Salter MA. Accelerated Interstitial High Dose Rate Brachytherapy as a

Boost Technique in the Treatment of Soft Tissue Sarcomas. 38th Annual Scientific Meeting of the

American Society for Therapeutic Radiology and Oncology; LA, California. October 27-30, 1996.

9. Raben D, Stackhouse M, Buchsbaum DJ, Mikheeva G, Khazaeli MB, McLean S, Kirkman R, Krasnykh V,

Curiel DT. Genetic Induction of the Gastrin Releasing Peptide Receptor on Tumor Cells for Radiolabeled Peptide Binding. International Journal Radiation Oncology Biol. Physics; 36(suppl

1):378, 1996.

10. Meyer JT, Hixson WC, Jennelle RLS, Alonso JE, Raben D, Spencer SS, Kim RY. Prophylactic Post-

Operative Radiotherapy Prevents Heterotopic Ossification Following Traumatic Cetabular Fracture.

38th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology; Los Angeles, California. October 27-30, 1996.

11. Raben D, Buchsbaum DJ, Mikheeva G, Grizzle WE, Khazaeli MD, Rogers B, Curiel DT, Garver RI, Jr. A to Augment Efficacy of Genetic Radiation Immunotherapy by use of Conditionally Replication-

Enabled Adenovirus. Cancer Gene Therapy 3:531, 1996.

12. Pederson LC, Vickers SM, Buchsbaum DJ, Raben D, Kancharla R, Curiel DT, Stackhouse MA. Molecular

Chemotherapy Combined with Radiation Therapy Enhances Killing of Cholangiocarcinoma. Gastroenterol 112:A 1464, 1997.


13. Buchsbaum DJ, Rogers BE, Raben D, McLean S, Laffoon K, Myracle A, Grimes C, Carpenter T, Bright S,

Olsen C, Curiel DT. Genetic Induction of Somatostatin Receptor in Tumor Cells Enhances Binding and Localization of Radiolabeled Octreotide; XII International Symposium on Radiopharmaceutical

Chemistry; Uppsala, Sweden. June 15-19, 1997.

14. Miller R, Rogers BE, Carpenter T, Douglas JT, Gillespie GY, Buchsbaum DJ, Curiel DT, Raben D.

Improved Radiolabeled Peptide Localization to Gliomas through the use of Targeted Adenoviral

Vectors. Cancer Gene Therapy 4:S30-S31, 1997.

15. Miller CR, Rogers BE, Carpenter T, Douglas JT, Gillespie GY, Raben D, Wells A, Buchsbaum DJ, Curiel DT. EGFR Targeted Adenovirus Gene Delivery. Keystone Conferences: The Molecular and Cellular

Biology of Gene Therapy; Keystone, Colorado. January 19-25, 1998.

16. Miller CR, Rogers BE, Douglas JT, Gillespie GY, Raben D, Buchsbaum DJ, Curiel DT. EGFR Targeted

Adenoviral Mediated Gene Delivery to Human Glioblastoma Tumors. 89th Annual Meeting,

Proceedings of the American Association of Cancer Research for AACR; New Orleans, Louisiana. March 28 – April 1, 1998.

17. Miller CR, Buchsbaum DJ, Carpenter T, Douglas J, Gillespie GY, Curiel DT, Raben D. Retargeting of

Adenovirus to the Epidermal Growth Factor Receptor Results in Efficient Gene Delivery to Cultured

and Primary Human Glioma Cells. 1st Annual Meeting, American Society of Gene Therapy; Seattle,

Washington. May 28-31, 1998.

18. Buchsbaum DJ, Roger BE, Raben D, Garver Jr. RJ, Grizzle WE, Khazael MB, Curiel DT. Genetic

Radioisotope Targeting Strategies for Cancer Localization and Therapy. 1st Annual Meeting, American Society of Gene Therapy; Seattle, Washington. May 28-31, 1998.

19. Urban D, Bueschen A, Kim R, Raben D, Pettus J. Iodine 125 Brachytherapy, A Minimally Invasive

Treatment for Localized Prostate Cancer: Preliminary Report. Journal of Endourology; 12(suppl 1),

16th World Congress on Endourology. New York, NY, September 3-6, 1998.

20. Raben D, Buchsbaum D, Gillespie G, Saleh M, Waksal H. Enhanced Survival of Nude Mice Bearing

Human Gliomas Treated with Concurrent Unlabeled Anti-epidermal Growth Factor Receptor (Anti- EGFr) Antibody and Irradiation. American Radium Society, Annual Meeting, Hawaii, April 17-21,

1999.

21. Raben D, Buchsbaum D, Gillespie G, Saleh M, Waksal H. Treatment of Human Intracranial Gliomas

with Chimeric Monoclonal Antibody against the Epidermal Growth Factor Receptor Increases

Survival of Nude Mice when treated Concurrently with Irradiation. 90th Annual Meeting, Procedings of the American Association of Cancer Research. Philadelphia, PA, April 10-14, 1999.

22. Kim Ry, Ezekiel MD, Zinsil T, Raben D, Bueschen AJ, Urban MD. Use of CT Based 3-D Images of the Pelvis to Circumvent Public Arch Interference during Transperineal Prostate Implantation.

Radiology 209, 1998.

23. Soriano A, Helfrich S, Holden S, Chan D, Raben D, Bunn P. Synergistic Effects of Chemotherapy (CT)

or Radiation (RT) and Herceptin against Human Non-Small Cell Lung Cancer (NSCL) Expressing the


HER-2/new Receptor. 12th International Conference on Monoclonal Antibodies for Cancer, San

Diego, CA. October 14-16, 1999.

24. Spencer SA, Childs HA, Tincher SA, Raben D, Bonner JA, Robert F. Final Results of a Phase I Study of

Combined UFT Plus Leucovorin and Radiation Therapy for Pancreatic Cancer. 41st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology. San Antonio, Texas.

October 31, 1999.

25. Bunn P, Soriano A, Helfrich B, Raben D, Holden S, Chan D, Garcia M. HER2/neu Expression and

Effects of Herceptin alone and in Combination with Cytotoxic Agents in Lung Cancer. 91st Annual

Meeting, Procedings of the American Association of Cancer Research. San Francisco, California,

April 1-5, 2000.

26. Batuello JT, Gamito EJ, Crawford D., Partin AW, McLeod R, Stock R, Stone S, Raben D. Artificial Neural

Network to Predict Risk of Lymph Node Spread in Men with Clinically Localized Prostate Cancer and

Method to Improve Utility of ANN Output. 36th Annual Meeting, Procedings of the American Society

of Clinical Oncology, New Orleans, Louisiana, May 20-23, 2000.

27. Raben D, Helfrich B, Phistry M, Chan D, Bunn P. ZD1839 (Iressa), an EGFR-TKI Potentiates Radiation/Chemotherapy Cytotoxicity in Human Non-Small Cell Lung Cancer Cell Lines (NSCLC),

11th AACR-NCI-EORTC Special Conference in Cancer Research, Amsterdam, November 6-11, 2000.

28. Raben D, Phistry M, Helfrich B, Chan D, Bunn P. ZD1839 (Iressa), A Selective Epidermal Growth

Factor (EGFR)-Tyrosine Kinase Inhibitor (TKI), Appears to Enhance Radiation (RT) Induced

Cytotoxicity in Human Pancreatic and Cholangiocarcinoma Cell Lines in Vitro, 1st Annual MDACC Gastrointestinal Cancer Conference, Orlando, FL, November 16-18, 2000.

29. Helfrich B, Phistry M, Chan D, Oliver T, Bunn P, Raben D. ZD1839 (Iressa), A Selective EGFR-TKI Enhances Radiation and Chemotherapy Cytotoxicity in EGFR Positive Human Non-Small Cell Lung

Cancer Cells (NSCLC) In Vitro. AACR, Maui, Hawaii, February 12-16, 2001.

30. Raben D, Helfrich B, Chan D, Phistry M, Kee A, Zhao T, Zundel W, Bunn P. C225 Anti-EGFR Antibody

Potentiates Radiation (RT) and Chemotherapy (CT) Cytotoxicity in Human Non-Small Cell Lung Cancer (NSCLS) Cells in Vitro and In Vivo, 37th Annual Meeting, Proceedings of the American Society

of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

31. Raben A, Grebler A, Ivker R, Geltzeiler J, Yang J, Shoengold S, Helfman A, Raben D, Baron A, Zeng C,

Coia L. Patterns and Predictors of Acute Toxicity after HDR Brachytherapy and 3D-CRT for Localized

Prostate Cancer: Preliminary Results of Phase I-II Dose Escalation Study, Annual Meeting of the American Brachytherapy Society, Vancouver, Canada, May 19-22, 2001.

32. Gamito E, Crawford D, O’Donnell C, Han M, Partin A, Tewari A, Errejon A, Raben D. Artificial Neural Network Model to Predict Risk of Non-Organ-Confined Disease and Risk of Lymph Node Spread in

Men with Clinically Localized Prostate Cancer. Proceedings of the American Society of Clinical

Oncology, 37th Annual Meeting, San Francisco, CA, May 12-15, 2001.

33. Raben D, Helfrich B, Chan D, Shogun T, Zundel W, Sclafani R, and Bunn PA. The Effects of ZD1839 on

Cell Signaling Processes and its Growth Effects With Radiation and Chemotherapy in Human Non-

Small Cell Lung Cancer Cells in Vitro. 12th AACR-NCI-EORTC Special Conference in Cancer Research,

Oct. 29-Nov.2, Miami Beach, FL, 2001.


34. Helfrich B, Raben D, Chan D, Garcia L, Shogun T, Zundel W, Hirsch F, Franklin W, Bunn P. C225 anti-

epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo. ASTRO 43rd Annual

Meeting, San Francisco, CA, November 4-8, 2001

35. Raben D, Chan D, Franklin W, Helfrich B, Garcia M, Bunn PA. Effect of EGF receptor inhibitors alone

and in combination with chemotherapy and radiotherapy on the growth of human lung cancer cell

lines. Proceedings of the SPORE Meeting, July 15-17, Washington, DC, 2002.

36. Eldridge B, Rabinovitch R, Berkey B, Raben D, Ang KK, Fu K. The Impact of Baseline Nutritional Support on Treatment Outcome in Patients with Locally Advanced Squamous Cell Cancer of the Head

and Neck Treated with Definitive Radiotherapy: Report of the Radiation Therapy Oncology Group

(RTOG) Trial 90-03. Proceedings of the 44th American Society Therapeutic Radiation Oncologists

(ASTRO), Int J. Radiat Oncol Biol Phys, (Abs.) October 4-8, New Orleans LA, 2002.

37. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, Paolo F, D’Armiento, Bianco AR, Tortora G, and Ciardiello F. ZD6126, a Novel Vascular Targeting Agent, Strongly Enhances the Effects

of Ionizing Radiation (RT) and ZD1839 (Iressa) in Human Non-Small Cell Lung Cancer (NSCLC).

Proceedings from 1st International Symposium on Signal Transduction Modulators in Cancer

Therapy. Amsterdam, September 23-25, 2002.

38. Raben D, Chan D, Helfrich B, Franklin W and Bunn PA. EGFR inhibition with ZD1839 (‘Iressa’) augments radiation therapy in non-small cell lung cancer (NSCLC): translation from pre-clinical to

clinical investigations. ASCO Molecular Targets Meeting, San Diego CA, Nov. 8-11, 2002.

39. Raben D. The Emerging Role of EGFR and COX-2 Inhibitors in the Treatment of Human Cancers:

Walk Before You Run! 12th International Conference of Radiation Research, Brisbane, Australia, August 18, 2003.

40. Raben D, Weng E, Kane M, et al. Preliminary report on toxicity of a phase I trial of gefitinib (IressaTM) in combination with radiation/chemotherapy for patients with locally advanced head and

neck cancer (LAHNC). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer

Therapeutics, Boston, MA, Nov. 17-21, 2003.

41. Raben A, Grebler A, Sim S, Geitzeller J, Keselman I, Litvin S, Geitzeller M, Raben D, Crawford D, and

Yang J. Analysis of acute and late morbidity and biochemical control for intermediate to high risk prostate cancer treated with androgen deprivation, HDR and 3D/IMRT: a 4 year results of a phase I-II

dose escalation trial. International Brachytherapy Meeting, Barcelona, Spain. Radiotherapy Oncology

GEC-ESTRO, Vol 71(suppl 2) May 15, 2004. Abst #105 (oral).

42. Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Jones C, Sur RK, Raben D, et al. Cetuximab prolongs

survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proceedings of the American

Society of Clinical Oncology, 40th Annual Meeting, New Orleans, LA 2004. Abst # 5507 (LBA).

43. Raben D, Kane M, Chen C, Song J, et al. Update on the toxicity and response of a phase I trial of

concurrent, daily gefitinib and radiation or chemo-radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN). 16th EORTC-NCI-AACR Symposium on


Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of

Cancer (Supp) Vol. 2(8), 2004.

44. Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Jones C, Sur RK, Raben D, et al. A phase III study of

radiation with or without cetuximab in local-regionally advanced head and neck cancer. Proceedings of the 46th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists

(ASTRO), Atlanta GA, Oct 3-8, 2004, Int J Radiat Oncol Biol Phys., Supp. 60(1), Abst # 31 S147.

45. Frederick B, Helfrich B and Raben D. Is Hypoxia Relevant in Modulating the Effects of ZD6474, An

Active Dual EGFR-VEGFR Tyrosine Kinase Inhibitor, in Head and Neck Cancer? 16th EORTC-NCI-

AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September

28, European Journal of Cancer (Supp) Vol. 2(8), 2004.

46. Helfrich B, Troiani T, Raben D, Frederick B, et al. Anticancer effects of ZD6474 in gefitinib

(IressaTM)-resistant lung cancer cell lines in vitro. 16th EORTC-NCI-AACR Symposium on Molecular

Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of Cancer

(Supp) Vol. 2(8), pp51, 2004.

47. Gustafson D, Merz A, Zirrolli J, Raben D. Impact of Scheduling on Combined VEGFR/EGFR Tyrosine Kinase Inhibition by ZD6474 and Radiotherapy in Human Head and Neck Tumor Xenografts. 16th

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland,

September 28, European Journal of Cancer (Supp) Vol. 2(8), 2004.

48. Raben D, Gustafson D, Frederick B, et al. Anti-tumor efficacy of ZD6474, a VEGFR tyrosine kinase

inhibitor with additional activity against EGFR tyrosine kinase, alone and in combination with radiotherapy in human head and neck cancer. Abstracts of the 3rd International Chicago Symposium

on Malignancies of the Chest and Head and Neck, Chicago, Ill, Lung Cancer 46: Suppl. 1, Abs. S24, Oct.

7-9, 2004.

49. Bianco C, Giovanetti E, Danesi R, Ciardiello F, Mey V, Tortora G, Gambardella U, Pasqualetti F, Nannizzi S, Cionini L, Raben D, Del Tacca M. Enhancement of cytotoxic activity of gemcitibine and

ionizing radiation by combined treatment with the VEGF and EGF receptor tyrosine kinase inhibitor

ZD6474 against pancreatic cancer cells in vitro. 96th Annual Meeting of the AACR, April 16-20, Anaheim, CA, 2005, PO.TB34. Radiation Biology 3, Abst # 4752.

50. B.A. Murphy, B. Shaktour, D. Raben, W. Reid, J. Netterville, B. Burkey, B. Kish, J. Song, M. Kane, A.J. Cmelak A Phase II Multi-Institutional Trial of Chemoradiation (CR) Using Weekly Docetaxel (Doc)

and Erythropoetin (Epo) for High-Risk Postoperative Head and Neck Cancer (HRHNC) Patients.

Proceedings of the American Society of Clinical Oncology, 41st Annual Meeting, May 13- 17, Orlando FL, 2005, Vol 23. No16S, Abstract # 5591.

51. Raben D, Chen C, Eckhardt GS, Kane M, Song J, Bemis L, Varella-Garcia, M, Brualdi L, Hu K, Quon H, and Dancey J. Maturing toxicity and outcomes of a phase I trial of concurrent daily gefitinib and

radiation or chemo-radiation for patients with locally advanced squamous cell carcinoma of the head

and neck. Proceedings of the 47th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Denver, CO, Oct 16-20, 2005, Int J Radiat Oncol Biol Phys., Supp.

60(1), Abstract # 2237.

52. Rothschild B, Frederick B, Helfrich B, Weed S, Shim A, Song J and Raben D. Combining the Src

Inhibitor, AZD0530, with Ionizing Radiation Yields Additive Effects Without Modulation of Phospho- Sites on Src, EGFR or MAPK. For poster presentation at AACR-NCI-EORTC International Conference


on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications,

Philadelphia, PA, Nov14-18th, 2006.

53. Chen H, Raben D, et al. KRAS Mutation Analysis in Patients with Locally Advanced Pancreatic Cancer

(LAPC) Treated with Gefitinib and Chemoradiation Therapy (CT-PCR) in Phase I Trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part II. Vol 24, No. 18S (June 20

Supplement), 2006: #4106.

54. Chen C, Damek D, Lillihei K, Raben D, et al. A Phase I dose escalation study of hypofractionated

stereotactic radiotherapy in combination with ZD1839 (Iressa TM) in patients with recurrent

malignant gliomas. Proceedings of the 48th Annual Scientific Meeting of the American Society

Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-9, 2006. Int J Radiat Oncol Biol

Phys., Supp. 66(3), Abstract # 1120.

55. McCammon R, Kavanagh B, Raben D, et al. Acute toxicity assessment of a single institution series of

prostate cancer patients treated with pelvic intensity modulated radiation therapy with synchronous

integrated boost to the prostate or prostate bed. Proceedings of the 48th Annual Scientific Meeting of

the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-9, 2006.

Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2277.

56. Olsen C, Kavanagh B, Raben D, et al. Stereotactic body radiation therapy (SBRT) vs high dose rate

brachytherapy (HDR) as hypofractyionated radiation therapy for prostate cancer: a comparison of

achievable tumor and normal tissue doses. Proceedings of the 48th Annual Scientific Meeting of the

American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-9, 2006. Int J

Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2310.

57. Bianco C, Giovanetti E, Ciardiello F, Mey V, Nanizzi S, Pasqualetti F, Troiani T, Raben D, et al.

Synergistic antitumor activity of ZD6474, an inhibitor of VEGFR and EGFR signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Proceedings of the 48th Annual

Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-9, 2006. Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2162.

58. Bonner, JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, Raben D, et al. Prolongation of survival with the addition of cetuximab to radiation in patients with locoregionally advanced head and neck cancer

(SCCHN): Five-year results from a randomized trial. American Society for Therapeutic Radiology and

Oncology 2008 Annual Meeting Late breaking Abstracts Int J Radiat Oncol Biol Phys. 1 September 2008 (Vol. 72, Issue 1, Pages e1-e4, DOI: 10.1016/S0360- 3016(08)03646-8) (LB3).

59. Lopez-Skinner L, Kelley L, Gatesman-Ammer A, Rothschild B, Frederick B, Raben D, Green T, Flynn D and Weed West S. The novel Src/Abl kinase inhibitor AZD0530 inhitbits proliferation, invasion and

invadopodia formation in head and neck squamous cell carcinoma. Proceedings of the100th AACR

Meeting, Denver, CO. Apr 18-22, 2009. Abstract #3247

60. Amanda Gatesman Ammer, Laura C. Kelley, Karen E. Hayes, Jason V. Evans, Lesly Ann Lopez- Skinner,

Karen H. Martin, Brian L. Rothschild, Barbara Frederick, David Raben, Tim P. Green, Scott A. Weed. West Virginia Univ. Health Sciences Ctr., Morgantown, WV, University of Colorado Denver, Aurora,

CO, AstraZeneca Phamaceuticals, Cheshire, United Kingdom. The Src inhibitor AZD0530 suppresses

head and neck squamous cell carcinoma invasion by disrupting invadopodia activity. Proceedings of

the100th AACR Meeting, Denver, CO. Apr 18-22, 2009. Abstract #3772


61. Sclafani R, Siriwardana S, Frederick B, Stahringer S, Tyagi A, Jimeno A, Agarwal A, Raben D.

Combined Resveratrol and radiation therapy in head and neck cancer. Abstract #University of Colorado Denver School of Medicine. Aurora, CO. University of Colorado School of Pharmacy, Aurora,

CO. Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-22, 2009Abstract #3989

62. Barbara Frederick, Barbara Helfrich, Ashley Fletcher, David Raben. University of Colorado Denver, Aurora, CO. The Src inhibitor AZD0530 induces autophagy in head and neck squamous cell carcinoma

and non-small cell lung cancer cell lines. Proceedings of the 100th AACR Meeting, Denver, CO April

18-22, 2009#392

63. Aik Choon Tan, Ryan Anderson, Barbara Frederick, David Raben, Antonio Jimeno. University of

Colorado Denver, Aurora, CO. Pathway-based comparison approach for the identification of

responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC) Proceedings of

the100th AACR Meeting, Denver, CO. Apr 18-22, 2009Abstract #4702

64. Marianne E. Marshall, Scott A. Kono, Brady Bichon, Linsday A. Marek, Barbara A. Frederick, David

Raben, Lynn E. Heasley. Univ. of Colorado, Aurora, CO 5232 Autocrine signaling by FGFs and FGFRs

in HNSCC cells Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-22, 2009Abstract #5232

65. Ian J. Stratford, Brian` Telfer, Tim P. Green, Paul Elvin, Anderson Ryan, David Raben, Stephen R. Wedge. Univ. of Manchester School of Pharmacy, Manchester, United Kingdom, Cancer Bioscience,

AstraZeneca, United Kingdom, University of Colorado Denver, Aurora, CO. Inhibition of metastatic

dissemination following loco-regional control of a primary tumor: examining a novel treatment

paradigm with the Src kinase inhibitor AZD0530. Proceedings of the100th AACR Meeting, Denver,

CO. Apr 18-22, 2009Abstract #4946

66. Impact of Correcting Anatomic Distortions on Daily Delivered Doses in Post-Prostatectomy Patients

M. Miften, Q. Diot, L. Gaspar, D. Raben, J. Martinez, T. Schuchman, B. Kavanagh Department of

Radiation Oncology, University of Colorado Denver, Aurora, CO

67. Metabolic Tumor Volume and Oropharynx Subsite as Prognostic Factors in Advanced Head and Neck Cancer. D. Raben, C. Chen, B. Loo, E. Graves, B. Kavanagh, University of Colorado Cancer Center,

Aurora, CO, Stanford University, Palo Alto, CA Abstract #2124

68. The PARP1 inhibitor olaparib (AZD2281) enhances radiation-induced DNA damage in BRCA1/BRCA2

wild-type head and neck squamous cell carcinoma cell lines. Frederick B, Fletcher A, Raben D.

University of Colorado Denver, Aurora CO. Mol Cancer Ther 2009;8(12 Suppl):A118.

69. Preliminary Outcomes for Treatment of High Intermediate-and High Risk Prostate Cancer Patients

using Pelvic Intensity-Modulated Radiotherapy with Hypofractionated Simulataneous Integrated Boost to Prostate. Reddy K, Nelson BC, McCammon R, Rusthoven KE, Newman F, Kavanagh B, Raben

D. University of Colorado Denver, Aurora CO. Abstract #570.

70. Phase I Trial of Concurrent Bortezomib, Paclitaxel, and External Beam Radiation in Patients with

Unresectable Pancreatic or Billiary Cancer. Pugh TJ, Schefter TE, Kane M, Eckhardt SG, McCarter M,

Chen YK, Swing R, Draheim L, Raben D. University of Colorado Denver, Aurora CO. Abstract#2538

71. Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single

Fraction Equivalent Dose of Local Control. Stinauer M, Kavanagh B, Schefter TE, Gonzalez R, Flaig T,

Lewis K, Robinson W, Chidel M, Glode M, Raben D. University of Colorado Denver, Aurora CO.

Abstract#569.


72. The Role of Health Locus of Control in the Continued use of Alcohol and Tobacco in Head and Neck

Cancer Survivors. Shih S, Madore A, Bevan A, Costenaro A, Anderson D, Raben D, Allen J, Kilbourn K. The Ohio State University, Columbus OH, University of Colorado Denver, Aurora CO. Abstract#0175.

Active or Recently Completed Protocols 1. NCI-CTEP sponsored multi-institutional Phase I/II study of Iressa, radiation and cisplatin for patients

with locally advanced head and neck cancer. (accrual completed).

Principal Radiation Oncology Investigator: David Raben, M.D.

2. Millennium Pharmaceuticals sponsored Phase I study of Bortezomib and concurrent radiation in

patients with advanced malignancies (currently accruing).


3. Astra-Zeneca sponsored Phase II randomized, double blind, placebo controlled, multicenter

comparative study of ZD1839 250 mg or 500 mg (IressaTM) given either continuously or

concomitantly with cisplatin plus radiotherapy for the treatment of patients with previously

untreated unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma.

(accrual completed).


4. Astra-Zeneca sponsored single institution phase I/II study of Iressa in combination with paclitaxel

and radiation in patients with locally advanced, unresectable carcinoma of the pancreas. (accrual

completed)


5. AstraZeneca sponsored Multi-Center Phase I/II study of Iressa in Combination With External Beam

Radiation and Chemotherapy With Consolidation Carboplatin/Paclitaxel Followed By Maintenance Iressa in Untreated Patients With Locally Advanced (Stage III), Non-Small Cell Lung Cancer (NSCLC).

(closed early due to poor accrual)


6. Millennium Pharmaceuticals sponsored Phase I study of Bortezomib and concurrent

radiation/paclitaxel in patients with locally advanced pancreatic carcinoma or cholangiocarcinoma. (closed to accrual)


7. Phase I/II study of erlotinib (TarcevaTM) with conformal 3-D re-irradiation in patients with locally

recurrent squamous cell cancer of the head and neck (completed)

Co-Principal Radiation Oncology Investigator: David Raben, M.D

8. AstraZeneca sponsored multi-institutional phase I/II trial combining ZD6474, a dual EGFR- VEGFR

tyrosine kinase inhibitor, in combination with radiotherapy or chemo-radiotherapy for patients with locally advanced, unresectable stage III/IV squamous cell cancer of the head and neck. (accrual

completed)


9. RTOG 0619: A Phase I /II trial of induction ZD6474 followed by surgery followed by chemoradiation plus ZD6474 for high risk postoperative advanced squamous cell carcinoma of the head and neck.

(closed to accrual)



10. Phase I trial of Olaparib, an Oral PARP inhibitor with Radiation after Induction TPF for Patients with

Locally Advanced, HPV Negative Head and Neck Cancer. Principal Radiation Oncology Investigator: David Raben, M.D.

(currently accruing)

Administrative Responsibilities

International Medical Committee Responsibilities: Assist in building international outreach medical services, collaborations for research and

clinical treatment of patients with locally advanced cancers

Documents

Raben, D. Curriculum Vitae 1 | P a g e Raben CV 6... · Raben, D. Curriculum Vitae 1 | P a g e David Raben, MD June 1, 2017 Professor And Associate Scientist